Form 4: BiomX CEO Jonathan Solomon Receives Grant of Restricted Stock Units
SEC Form 4
BiomX Inc. CEO Jonathan Eitan Solomon reports the acquisition of 50,556 Restricted Stock Units (RSUs) that are immediately vested and convertible to common stock.
Summary
- On September 16, 2024, Jonathan Eitan Solomon, CEO of BiomX Inc., acquired 50,556 Restricted Stock Units (RSUs).
- The RSUs are immediately vested and convert into BiomX Inc.'s common stock on a one-for-one basis.
- Following the transaction, Solomon directly owns 53,056 shares of common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a standard executive compensation practice.
Positives
- The grant of RSUs to the CEO could align his interests with those of the shareholders.
Industry Context
This type of equity compensation is common for aligning executive incentives with company performance in the biotechnology industry.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Regeneron routinely use RSUs and stock options to incentivize their leadership teams.
- The size of the grant is relative to the company's market capitalization and the executive's role.
Stakeholder Impact
- The RSU grant could positively impact shareholders by aligning the CEO's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of transaction: Jonathan Solomon acquired 50,556 Restricted Stock Units. |
| 09/18/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.